ORLANDO, FL — September 10, 2025 — Leads & Copy — Exousia Pro, Inc. (OTCPINK:MAJI) has announced a key strategic milestone towards expanding its commercial footprint and building significant shareholder value. The clinical-stage biotechnology company and innovator in exosome-based therapies has filed a new Provisional Patent (#63/877,517) that embodies a groundbreaking method for loading Extracellular Vesicles (EVs), poised to give the company a significant competitive advantage.
The new provisional patent, utilized under the company’s Exousia Health division, covers a novel process for encapsulating active compounds into naturally-secreted vesicles known as exosomes. The method is designed to enhance loading efficiency and improve the stability and delivery of therapeutic agents with applications across the pharmaceutical, nutraceutical, and cosmetics markets. The global pharmaceutical market is a multi-trillion dollar industry, with an estimated size of $1.77 trillion in 2025. The global nutraceuticals market is valued at over $500 billion in 2025 and the global cosmetics market is valued at over $450 billion in 2025.
Matt Dwyer, President of Exousia Pro, Inc. said the filing of this provisional patent marks a pivotal moment for Exousia Pro, as it represents one of two new patent-ready technologies in development. He added that this proprietary technology is a critical asset that will provide a powerful market edge, enabling the company to develop and introduce new, innovative products with enhanced efficacy for its growing patient base within Exousia Health, and beyond. The company is actively preparing to file for trademarks on several new products that will leverage this loading method, further expanding revenue opportunities and bringing tangible value to shareholders.
Exousia Pro (formerly Marijuana, Inc.) is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology.The company’s patented manufacturing process utilizes plant-based materials to create exosomes used in commercial applications, from dermatology to dentistry. The company’s proprietary loading technology can infuse a range of molecules from drugs to DNA.
Investor Relations
ir@exousiapro.com
Source: Exousia Pro, Inc.
